Endoscopic Instruments Patents: Top Companies & Trends 2026
- 64.5% concentration. The top five assignees alone account for 169 of 262 records in scope, with a long tail of single-digit filers behind them.
- Filings down 56% since the 2022 peak. Activity rose to 23 records in 2022, then fell to 7 by 2024 — the last year the dataset treats as complete.
- One subclass dominates the claim space. A61B covers 88.2% of the 262 records, meaning almost every filing touches core diagnosis-and-surgery claims regardless of its specific device type.
Filing growth compares 2021 (16 records) with 2024 (7) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 262 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks 262 published patent records filed between 2015 and mid-2026 that combine endoscopic surgical instruments or endoscopic energy devices with at least one of six functional claim areas: hemostasis clips, snare polypectomy, ultrasonic dissection, instrument channel design, tissue sealing, and smoke evacuation. The scope is deliberately functional rather than device-specific, so it captures both dedicated energy-delivery tools and the broader surgical instruments that integrate them.
Publication lags filing by roughly 18 months, so counts for 2025 and 2026 will keep rising as more applications publish; treat the most recent two years as incomplete rather than as evidence of a slowdown.
Filing trends and technology composition
The record set spans eleven years of publication activity across six receiving offices, with claim density concentrated in one core surgical subclass and thinner secondary activity in materials, informatics and optics.
Filings rose to a 2022 peak, then declined
Annual filings climbed from 4 records in 2017 to a peak of 23 in 2022, then fell to 7 by 2024 — a 56% decline over that three-year span. Figures for 2025 and 2026 are still filling in given the typical 18-month publication lag and should not yet be read as a continuing drop.
One subclass carries almost every record
A61B (diagnosis and surgery) appears in 88.2% of the 262 records in scope, dwarfing the next-largest classes: A61F implants and prostheses at 5.7%, and B29C plastics shaping and G16H healthcare informatics each at 4.6%. Because records can carry multiple IPC classes, these shares add up to more than 100% and should be read individually, not summed.
Shares are the percentage of the 262 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Endoscopic Instruments and Energy Devices with Eureka
This page is one run against one query. Ask Eureka your own question about endoscopic instruments and energy devices and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this field
US8784418B2 — Endoscopic surgical forceps
An end effector assembly for an endoscopic surgical instrument includes a pair of jaw members disposed in opposing relation relative to one another. One or both of the jaw members is moveable relative to the other between a spaced-apart position and an approximated position for grasping tissue therebetween. Each jaw member defines an arcuate configuration and includes a proximal segment and a distal segment coupled to the proximal segment, moveable between a use position and an insertion position.Filed by Covidien LP, published 2014-07-22 — included here as a representative record for the jaw-member and end-effector claim family that recurs across this landscape.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US8414577B2 | Surgical instruments and components for use in sterile environments | 1,883 |
| 2 | US8579937B2 | Tool member cover and cover deployment device | 1,686 |
| 3 | US8752264B2 | Surgical tissue sealer | 1,631 |
| 4 | US8475453B2 | Endoscopic vessel sealer and divider having a flexible articulating shaft | 1,499 |
| 5 | US9050120B2 | Apparatus and method of user interface with alternate tool mode for robotic surgical tools | 1,484 |
| 6 | US5928137A | System and method for endoscopic imaging and endosurgery | 1,477 |
| 7 | US8968312B2 | Surgical device with powered articulation wrist rotation | 1,454 |
| 8 | US6221007B1 | System and method for endoscopic imaging and endosurgery | 1,378 |
| 9 | US9204924B2 | Endoscopic vessel sealer and divider having a flexible articulating shaft | 1,017 |
| 10 | US9192434B2 | Gap control via overmold teeth and hard stops | 1,012 |
Citation counts favour older records simply by virtue of longer exposure to a searched corpus — read them as a signal of influence on later filings, not as a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the ranking, the trend and the class composition are read together: heavy concentration at the top, a peak that has already passed, and a claim space almost entirely anchored to one IPC subclass.
Five companies hold nearly two-thirds of the field
The leader alone holds 100 records; the gap to fifth place (13) is steep, and the gap to tenth (7) is steeper still. This is not a fragmented field — a small group of assignees has built dense, overlapping claim positions around the core instrument and energy-delivery designs.
Activity has cooled from its 2022 peak
Filings rose steadily through the late 2010s, peaked at 23 records in 2022, and have since fallen to 7 by 2024 — the last year the dataset treats as complete. That decline sits alongside near-zero recent-year filings from several of the largest historical assignees, suggesting consolidation of existing positions rather than active new claim-building.
Almost every filing sits inside one core subclass
A61B (diagnosis and surgery) appears in the vast majority of records, meaning claim space in the core mechanical and energy-delivery functions is heavily occupied. Secondary classes — implants, plastics shaping, informatics, optics — are each claimed by under 6% of records, which is where less-crowded ground exists.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to endoscopic instruments and energy devices, with the prior art for and against each one.
Assignee landscape and recent momentum
The ranking covers 46 companies across the full record set, with filings concentrated at the top and a long tail of entrants holding only a handful of records each. Several of the largest historical filers show no activity in the latest year, which is more consistent with a maturing, well-defended claim base than with an actively expanding one.
One assignee holds well over a third of all records
The top-ranked company's 100 records dwarf the fifth-place total of 13, pointing to a single dominant filer whose claim scope likely sets the boundaries other entrants have to design around.
The tail thins quickly past the top five
Record counts fall by nearly half between fifth and tenth place, and continue falling from there — most of the 46 ranked companies hold only a small number of records each.
Leading historical filers show no latest-year activity
Multiple of the largest assignees by cumulative record count, including one with a -100% year-over-year change, show zero filings in the most recent year. That pattern is consistent with defending existing positions rather than pursuing new claim territory, though the most recent years are still under-counted due to publication lag.
| Assignee | Recent year | YoY |
|---|---|---|
| Covidien LP | 0 | — |
| Ethicon Endo-Surgery, Inc. | 0 | — |
| Creo Medical Ltd | 0 | — |
| Cilag GmbH International | 0 | -100% |
| Versitech Limited | 0 | — |
| VALENTX | 0 | — |
| YOON INBAE | 0 | — |
| GREEN PHILIP S | 0 | — |
Where to take this analysis
The dataset points to a mature core and a thinner set of adjacent branches. The next steps depend on whether the goal is defensive clearance or identifying open filing ground.
Map freedom-to-operate against the top assignees
With five companies holding 64.5% of records, a freedom-to-operate review should start with the leader's claim scope before checking the rest of the ranked field.
Explore assignee claims in Eureka →Test claim language against secondary IPC classes
Classes like G16H and G02B carry a fraction of the records A61B does, which is where narrower, more defensible claims may still be available.
Run a white space search in Eureka →Track the most-cited records for downstream risk
The highest-citation records in this set are over a decade old; check whether their claims have been narrowed, licensed or challenged before assuming they still block current designs.
Check citation history in Eureka →Common questions about this landscape
One assignee leads the ranked field with 100 of the 262 records in scope, well ahead of the fifth-ranked company at 13. The top five companies combined hold 169 records, or 64.5% of the total, so the field is concentrated rather than fragmented. Beyond the top ten, which together hold 80.9% of records, the remaining 36 ranked companies each hold only a small handful.
Filings grew from 4 records in 2017 to a peak of 23 in 2022, then fell to 7 by 2024, a 56% decline over that three-year span. However, publication typically lags filing by around 18 months, so 2025 and 2026 counts are still incomplete and should not be read as confirming a continued fall. The honest reading is that the field passed a filing peak in 2022 and cooled through the most recently complete year.
The overwhelming majority of records, 88.2% of the 262 in scope, fall under IPC subclass A61B for diagnosis and surgery, which covers most instrument and energy-delivery mechanics. Secondary classes include A61F for implants and prostheses at 5.7%, and B29C plastics shaping and G16H healthcare informatics each at 4.6%. Because a single record can carry multiple classes, these percentages should be read individually rather than summed.
Several of the assignees with the largest cumulative record counts show zero filings in the most recent year, including one company with a -100% year-over-year change. That pattern suggests consolidation around existing claim positions rather than active expansion, though recent-year figures across the whole dataset are undercounted due to publication lag. A clearer read on current activity will only be possible once 2025 and 2026 filings finish publishing.
The clearest gaps sit outside the dominant A61B subclass, in areas like smoke evacuation filtration, healthcare informatics integration, and optical system components, each represented in under 6% of the 262 records. These are not untouched areas, but they carry far fewer competing claims than the core end-effector and energy-delivery mechanics. A freedom-to-operate check against the top five assignees is still the right first step before filing into any of these narrower branches.
Research Endoscopic Instruments and Energy Devices in depth with Eureka
Go past this page: query the whole endoscopic instruments and energy devices corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.